2.50
Hdl Handle:
http://hdl.handle.net/10541/55817
Title:
Current treatment approaches for diffuse large B-cell lymphoma.
Authors:
Illidge, Timothy M ( 0000-0003-3191-7324 ) ; Tolan, Shaun
Abstract:
There have been two major developments over the last decade that has led to improvements in outcome and longer survival for patients with diffuse large B-cell lymphoma (DLBCL). These developments have been firstly to increase the dose of active cytotoxic drugs and shorten the time between cycles, resulting in dose-dense and/or dose-intense regimens and secondly the addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy. Both strategies have been associated with higher response rates, lower relapse rates, longer event-free survival (EFS) and improved overall survival (OS), particularly in better prognostic groups. A combination of dose-dense and dose-intense chemotherapy regimens plus rituximab is currently being tested to confirm that the use of both approaches confers survival advantage. High-risk, poorer-prognosis DLBCL remains a challenge, and new treatment strategies are required for these patients. Improvements in outcome may potentially be achieved through a greater understanding of the genetic abnormalities specifically associated with poorer-prognosis disease, and factors that lead to unresponsiveness to chemotherapy. The role of radiotherapy is currently less clearly defined than at anytime in the management of DLBCL and the current evidence for using radiotherapy in this disease is therefore rigorously reviewed.
Affiliation:
School of Cancer Imaging Sciences, CR UK Paterson Institute for Cancer Research, University of Manchester, Manchester M20 4BX, UK. tmi@manchester.ac.uk
Citation:
Current treatment approaches for diffuse large B-cell lymphoma. 2008, 49 (4):663-76 Leuk. Lymphoma
Journal:
Leukemia & Lymphoma
Issue Date:
Apr-2008
URI:
http://hdl.handle.net/10541/55817
DOI:
10.1080/10428190701882187
PubMed ID:
18398733
Type:
Article
Language:
en
ISSN:
1029-2403
Appears in Collections:
All Christie Publications ; Clinical Oncology; School of Cancer and Imaging Sciences

Full metadata record

DC FieldValue Language
dc.contributor.authorIllidge, Timothy M-
dc.contributor.authorTolan, Shaun-
dc.date.accessioned2009-03-16T17:10:50Z-
dc.date.available2009-03-16T17:10:50Z-
dc.date.issued2008-04-
dc.identifier.citationCurrent treatment approaches for diffuse large B-cell lymphoma. 2008, 49 (4):663-76 Leuk. Lymphomaen
dc.identifier.issn1029-2403-
dc.identifier.pmid18398733-
dc.identifier.doi10.1080/10428190701882187-
dc.identifier.urihttp://hdl.handle.net/10541/55817-
dc.description.abstractThere have been two major developments over the last decade that has led to improvements in outcome and longer survival for patients with diffuse large B-cell lymphoma (DLBCL). These developments have been firstly to increase the dose of active cytotoxic drugs and shorten the time between cycles, resulting in dose-dense and/or dose-intense regimens and secondly the addition of the anti-CD20 monoclonal antibody rituximab to chemotherapy. Both strategies have been associated with higher response rates, lower relapse rates, longer event-free survival (EFS) and improved overall survival (OS), particularly in better prognostic groups. A combination of dose-dense and dose-intense chemotherapy regimens plus rituximab is currently being tested to confirm that the use of both approaches confers survival advantage. High-risk, poorer-prognosis DLBCL remains a challenge, and new treatment strategies are required for these patients. Improvements in outcome may potentially be achieved through a greater understanding of the genetic abnormalities specifically associated with poorer-prognosis disease, and factors that lead to unresponsiveness to chemotherapy. The role of radiotherapy is currently less clearly defined than at anytime in the management of DLBCL and the current evidence for using radiotherapy in this disease is therefore rigorously reviewed.en
dc.language.isoenen
dc.subjectDiffuse Large B-cell Lymphomaen
dc.subjectRadiotherapyen
dc.subjectRituximaben
dc.subjectRadioimmunotherapyen
dc.subject.meshAntibodies, Monoclonal-
dc.subject.meshAntineoplastic Combined Chemotherapy Protocols-
dc.subject.meshCombined Modality Therapy-
dc.subject.meshHumans-
dc.subject.meshLymphoma, Large B-Cell, Diffuse-
dc.subject.meshTreatment Outcome-
dc.titleCurrent treatment approaches for diffuse large B-cell lymphoma.en
dc.typeArticleen
dc.contributor.departmentSchool of Cancer Imaging Sciences, CR UK Paterson Institute for Cancer Research, University of Manchester, Manchester M20 4BX, UK. tmi@manchester.ac.uken
dc.identifier.journalLeukemia & Lymphomaen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.